Organization (Other)
Centre Antoine Lacassagne
ClinicalTrials.gov lists Centre Antoine Lacassagne as lead sponsor of 65 trials. It has 66 active development programs and 23 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Centre Antoine Lacassagne: 65 lead-sponsored trials and 1 legal-entity registration.
Disease areas (51)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Breast Neoplasms | 15 |
| Head and Neck Neoplasms | 6 |
| Lung Neoplasms | 5 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Carcinoma, Squamous Cell | 4 |
Showing 5 of 51 disease areas.
Trials by start year as sponsor or collaborator (21)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 5 |
| 2024 | 1 |
| 2023 | 6 |
| 2022 | 2 |
| 2021 | 3 |
| 2020 | 7 |
| 2019 | 6 |
| 2018 | 1 |
| 2017 | 5 |
Showing 10 of 21 years.
Prediction, not a registry value: median 36 months or more (the model's horizon) from start to primary completion across 10 trials still running at the 2026-10-09 snapshot; 10 of 10 predicted trials reach the 36-month horizon; registered median of 34 months across 42 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (66)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| "Capecitabine" | Rectal Neoplasms | Phase 3 | 1 |
| "Capecitabine" | Colorectal Neoplasms | Phase 3 | 1 |
| SBRT | Sarcoma | Phase 2 | 1 |
| ATEZOLIZUMAB | Sarcoma | Phase 2 | 1 |
| CYCLOPHOSPHAMIDE | Lymphoma, Large B-Cell, Diffuse | Phase 2 | 1 |
Showing 5 of 66 active programs.
Approved assets (23)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Blood Sampling | 3 |
| "Capecitabine" | 4 |
| CYCLOPHOSPHAMIDE | 2 |
| DOCETAXEL | 2 |
| CISPLATIN | 2 |
Showing 5 of 23 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 33% hit target (n=21) | 33% on time (n=21) |
Journals published in (29)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| International journal of radiation oncology, biology, physics | 3 |
| European journal of nuclear medicine and molecular imaging | 2 |
| Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | 2 |
| Annals of oncology : official journal of the European Society for Medical Oncology | 1 |
| BMJ open | 1 |
Showing 5 of 29 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1 | 0 | 1987-05-19 |
Organization relationships (3)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Centre Hospitalier Universitaire de Nice | Co sponsors trial with | 1 |
| Association Française pour la Recherche Thermale | Co sponsors trial with | 1 |
| Thuasne | Co sponsors trial with | 1 |
Latest dated events (74)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-06-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 74 events.
Biomarker capability evidence (73)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| CD33 | Trial sponsor | Named in trial inclusion criteria |
| CISH | Trial sponsor | Named in trial inclusion criteria |
| EGFR | Trial sponsor | Named in trial inclusion criteria |
| ERBB2 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 73 evidence rows.
Biomarkers this organization publishes on (266)
Shown in this order: most publications first.
Showing 5 of 266 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.